Repurposing the antimalarial compound artemisinin as a novel therapy for inflammatory conditions

Morad, H. 2022. Repurposing the antimalarial compound artemisinin as a novel therapy for inflammatory conditions. Drug Repurposing II. Woburn House, London, UK 10 - 11 May 2022 The Biochemical Society.

TitleRepurposing the antimalarial compound artemisinin as a novel therapy for inflammatory conditions
AuthorsMorad, H.
Abstract

Immune cell chemotaxis to sites of pathogen invasion is critical for fighting infection, but in life-threatening conditions such as sepsis and Covid-19, excess activation of the innate immune system is thought to cause a damaging invasion of immune cells into tissues and an excessive release of cytokines. In these circumstances, tempering excessive activation of the innate immune system may, paradoxically, promote recovery. Here we describe the repurposing of the antimalarial compound artemisinin towards a novel treatment for inflammatory conditions characterised by over-activation of the innate immune system. We identify artemisinin (and its analogue artesunate) as a potent inhibitor of neutrophil and macrophage chemotaxis. Artemisinin released calcium from intracellular stores by inhibiting isoform-3 of Sarcoplasmic/Endoplasmic Reticulum Calcium Atpase (SERCA3). Inhibition was irreversible and inhibited by iron chelation, suggesting iron-catalysed alkylation of SERCA3 as the mechanism by which artemisinin inhibits immune cell motility. In murine infection models, artemisinin/artesunate potently suppressed innate immune cell invasion into both peritoneum and lung and inhibited the release of cytokines/chemokines and neutrophil extracellular traps (NETs). This work suggests that artemisinin and artesunate may have value as therapies in conditions such as sepsis and Covid-19 in which over-activation of the innate immune system causes tissue injury that can lead to death. From these data we proposed a clinical trial of artesunate for Covid-19 patients, which the WHO accepted and are now running as part of the ‘SOLIDARITY’ initiative.

Year2022
ConferenceDrug Repurposing II
PublisherThe Biochemical Society
Accepted author manuscript
Publication dates
Published10 May 2022
JournalBiochemical Society Transactions
Web address (URL) of conference proceedingshttps://www.eventsforce.net/biochemsoc/frontend/reg/thome.csp?pageID=64596&eventID=130&traceRedir=4
Web address (URL)https://www.eventsforce.net/biochemsoc/frontend/reg/absViewDocumentFE.csp?documentID=3504&eventID=130

Related outputs

In sepsis hydrogen peroxide release accompanies neutrophil chemotaxis to organs, artesunate prevents this neutrophil-mediated organ infiltration, cytokine storm and NET release
Morad, H. 2024. In sepsis hydrogen peroxide release accompanies neutrophil chemotaxis to organs, artesunate prevents this neutrophil-mediated organ infiltration, cytokine storm and NET release. International Conference on Vaccines and Immunology . Paris, France 17 - 18 Oct 2024 Scientific Collegium.

Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release
Morad, H.O.J., Luqman, S., Garcia Pinto, L., Cunningham, K., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A. 2022. Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release. Scientific Reports. 2022 (12) 11078. https://doi.org/10.1038/s41598-022-15214-6

Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release
Morad, H.O.J., Luqman, S., Pinto, L.G., Cunningham, K.P., Vilar, B., Clayton, G., Shankar-Hari, M. and McNaughton, P.A. 2022. Artemisinin inhibits neutrophil and macrophage chemotaxis, cytokine production and NET release. Scientific Reports. 12 (1), pp. 1-18. https://doi.org/10.1038/s41598-022-15214-6

TRPM2 ion channels steer neutrophils towards a source of hydrogen peroxide
Hassan Morad, Suaib Luqman, Chun-Hsiang Tan and Peter McNaughton 2021. TRPM2 ion channels steer neutrophils towards a source of hydrogen peroxide. Dynamic Cell IV. 14 - 19 Mar 2021 The Biochemical Society.

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug conjugates (ADcs)
Hoffmann, R.M., Mele, S., Cheung, A., Larcombe-Young, D., Bucaite, G., Sachouli, E., Zlatareva, I., Morad, H., Marlow, R., McDonnell, J.M., Figini, M., Lacy, K.E., Tutt, A.J.N., Spicer, J.F., Thurston, D.E., Karagiannis, S.N. and Crescioli, S. 2020. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug conjugates (ADcs). Scientific Reports. 10 (1), pp. 1-11. https://doi.org/10.1038/s41598-020-65860-x

O30 Natural compounds affecting neutrophil migration
Hassan Morad, Suaib Luqman and Peter McNaughton 2017. O30 Natural compounds affecting neutrophil migration. ICMAN/ IUPHAR Natural Products. Aberdeen, Scotland 27 - 29 Sep 2017 Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2017.06.095

O30 Natural compounds affecting neutrophil migration
Morad, H., Luqman, S. and McNaughton, P. 2017. O30 Natural compounds affecting neutrophil migration. Biochemical Pharmacology. 139 (1), p. 119. https://doi.org/10.1016/j.bcp.2017.06.095

Time-course analysis of C3a and C5a quantifies the coupling between the upper and terminal Complement pathways in vitro
Morad, H. 2014. Time-course analysis of C3a and C5a quantifies the coupling between the upper and terminal Complement pathways in vitro. Royal Society of Medicine, Clinical Immunology and Allergy Conference. University of Cambridge Sep - Oct 2014 Royal Society of Medicine.

Permalink - https://westminsterresearch.westminster.ac.uk/item/wqxv1/repurposing-the-antimalarial-compound-artemisinin-as-a-novel-therapy-for-inflammatory-conditions


Share this

Usage statistics

25 total views
7 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.